Heidi L. Wagner

Insider · Director · WVE

Heidi L. Wagner files insider transactions with the SEC as a director of Wave Life Sciences (WVE). We hold 1 disclosed purchase or sale filed since 8 October 2015, 1 of them in the last 90 days.

Files forWVE
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure13 August 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 4 September 2019 — 11 August 2026Director · Wave Life Sciences (WVE)17 Form 4 lines · source: SEC Form 4
Filed 1 October 2015 — 28 February 2018SVP, Global Government Affairs · Alexion Pharmaceuticals (ALXN)35 Form 4 lines · source: SEC Form 4

Everything they disclosed

52 entries, newest first — one per disclosure report, one per Form 4 line

exercised options over 7,000 shares of Wave Life SciencesSEC Form 413 August 2026Common Stock · traded 11 August 2026 · filed 13 August 2026
▼ sold on the open market 7,000 shares of Wave Life SciencesSEC Form 413 August 2026Common Stock · traded 11 August 2026 · filed 13 August 2026
exercised options over 7,000 shares of Wave Life Sciences (a derivative holding)SEC Form 413 August 2026Stock Option (right to buy) · traded 11 August 2026 · filed 13 August 2026
exercised options over 14,000 shares of Wave Life Sciences (a derivative holding)SEC Form 410 December 2025Share Option (right to buy) · traded 8 December 2025 · filed 10 December 2025
exercised options over 7,000 shares of Wave Life SciencesSEC Form 410 December 2025Ordinary Shares · traded 8 December 2025 · filed 10 December 2025
▼ sold on the open market 7,000 shares of Wave Life SciencesSEC Form 410 December 2025Ordinary Shares · traded 8 December 2025 · filed 10 December 2025
exercised options over 7,000 shares of Wave Life SciencesSEC Form 410 December 2025Ordinary Shares · traded 8 December 2025 · filed 10 December 2025
▼ sold on the open market 7,000 shares of Wave Life SciencesSEC Form 410 December 2025Ordinary Shares · traded 8 December 2025 · filed 10 December 2025
was granted 76,200 shares of Wave Life Sciences (a derivative holding)SEC Form 413 August 2025Share Option (right to buy) · traded 11 August 2025 · filed 13 August 2025
was granted 12,700 shares of Wave Life SciencesSEC Form 413 August 2025Ordinary Shares · traded 11 August 2025 · filed 13 August 2025
was granted 64,460 shares of Wave Life Sciences (a derivative holding)SEC Form 414 August 2024Share Option (right to buy) · traded 12 August 2024 · filed 14 August 2024
was granted 32,230 shares of Wave Life SciencesSEC Form 414 August 2024Ordinary Shares · traded 12 August 2024 · filed 14 August 2024
was granted 45,000 shares of Wave Life Sciences (a derivative holding)SEC Form 49 August 2023Share Option (right to buy) · traded 7 August 2023 · filed 9 August 2023
was granted 21,000 shares of Wave Life Sciences (a derivative holding)SEC Form 417 August 2022Share Option (right to buy) · traded 15 August 2022 · filed 17 August 2022
was granted 21,000 shares of Wave Life Sciences (a derivative holding)SEC Form 418 August 2021Share Option (right to buy) · traded 16 August 2021 · filed 18 August 2021
was granted 10,500 shares of Wave Life Sciences (a derivative holding)SEC Form 420 August 2020Share Option (right to buy) · traded 18 August 2020 · filed 20 August 2020
was granted 21,000 shares of Wave Life Sciences (a derivative holding)SEC Form 46 September 2019Share Option (right to buy) · traded 4 September 2019 · filed 6 September 2019
▼ sold on the open market 244 shares of Alexion PharmaceuticalsSEC Form 41 March 2018Common Stock, par value $.0001 per share · traded 27 February 2018 · filed 1 March 2018
▼ sold on the open market 454 shares of Alexion PharmaceuticalsSEC Form 41 March 2018Common Stock, par value $.0001 per share · traded 28 February 2018 · filed 1 March 2018
was granted 14,577 shares of Alexion PharmaceuticalsSEC Form 48 February 2018Common Stock, par value $.0001 per share · traded 6 February 2018 · filed 8 February 2018
was granted 4,400 shares of Alexion PharmaceuticalsSEC Form 48 February 2018Common Stock, par value $.0001 per share · traded 6 February 2018 · filed 8 February 2018
▼ sold on the open market 1,774 shares of Alexion PharmaceuticalsSEC Form 48 February 2018Common Stock, par value $.0001 per share · traded 8 February 2018 · filed 8 February 2018
▼ sold on the open market 655 shares of Alexion PharmaceuticalsSEC Form 47 February 2018Common Stock, par value $.0001 per share · traded 5 February 2018 · filed 7 February 2018
▼ sold on the open market 120 shares of Alexion PharmaceuticalsSEC Form 44 October 2017Common Stock, par value $.0001 per share · traded 2 October 2017 · filed 4 October 2017
▼ sold on the open market 358 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 27 February 2017 · filed 1 March 2017
▼ sold on the open market 480 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 28 February 2017 · filed 1 March 2017
▼ sold on the open market 156 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 1 March 2017 · filed 1 March 2017
was granted 4,400 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 28 February 2017 · filed 1 March 2017
was granted 8,700 shares of Alexion Pharmaceuticals (a derivative holding)SEC Form 41 March 2017Option to Purchase Common Stock · traded 28 February 2017 · filed 1 March 2017
▼ sold on the open market 1,695 shares of Alexion PharmaceuticalsSEC Form 48 February 2017Common Stock, par value $.0001 per share · traded 6 February 2017 · filed 8 February 2017
▼ sold on the open market 15 shares of Alexion PharmaceuticalsSEC Form 48 February 2017Common Stock, par value $.0001 per share · traded 6 February 2017 · filed 8 February 2017
▼ sold on the open market 222 shares of Alexion PharmaceuticalsSEC Form 48 February 2017Common Stock, par value $.0001 per share · traded 7 February 2017 · filed 8 February 2017
▼ sold on the open market 59 shares of Alexion PharmaceuticalsSEC Form 416 November 2016Common Stock, par value $.0001 per share · traded 14 November 2016 · filed 16 November 2016
▼ sold on the open market 120 shares of Alexion PharmaceuticalsSEC Form 45 October 2016Common Stock, par value $.0001 per share · traded 3 October 2016 · filed 5 October 2016
▼ sold on the open market 222 shares of Alexion PharmaceuticalsSEC Form 410 August 2016Common Stock, par value $.0001 per share · traded 8 August 2016 · filed 10 August 2016
▼ sold on the open market 53 shares of Alexion PharmaceuticalsSEC Form 413 May 2016Common Stock, par value $.0001 per share · traded 13 May 2016 · filed 13 May 2016
was granted 3,000 shares of Alexion PharmaceuticalsSEC Form 41 March 2016Common Stock, par value $.0001 per share · traded 26 February 2016 · filed 1 March 2016
▼ sold on the open market 547 shares of Alexion PharmaceuticalsSEC Form 41 March 2016Common Stock, par value $.0001 per share · traded 29 February 2016 · filed 1 March 2016
was granted 21,000 shares of Alexion Pharmaceuticals (a derivative holding)SEC Form 41 March 2016Option to Purchase Common Stock · traded 26 February 2016 · filed 1 March 2016
▼ sold on the open market 166 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 4 February 2016 · filed 8 February 2016
▼ sold on the open market 3 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 4 February 2016 · filed 8 February 2016
was granted 6,129 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 4 February 2016 · filed 8 February 2016
▼ sold on the open market 200 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 100 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 220 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 200 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 277 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 250 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 8 February 2016 · filed 8 February 2016
▼ sold on the open market 28 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 8 February 2016 · filed 8 February 2016
▼ sold on the open market 664 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 8 February 2016 · filed 8 February 2016
was granted 1,000 shares of Alexion PharmaceuticalsSEC Form 48 October 2015Common Stock, par value $.0001 per share · traded 1 October 2015 · filed 8 October 2015
was granted 5,000 shares of Alexion Pharmaceuticals (a derivative holding)SEC Form 48 October 2015Option to Purchase Common Stock · traded 1 October 2015 · filed 8 October 2015

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.